Ferric carboxymaltose

DelveInsight's report on Iron Deficiency Anemia covers epidemiology, market trends in the US, EU4, UK, and Japan. Key trials include Dr. P. Noordzij's study on postoperative iron deficiency anemia treatment and RDC Clinical Pty Ltd's trial on IHAT. The US had 9.5 million prevalent cases in 2023, with females accounting for 65% of cases. Leading companies and therapies are highlighted, including MegaPro Biomedical's MPB-1514 and Pharmacosmos A/S's Ferric Derisomaltose. The report also discusses treatment strategies and market dynamics.

Restless legs syndrome (RLS) involves an urge to move legs, often worsening at rest, affecting sleep and quality of life. The American Academy of Sleep Medicine (AASM) updated guidelines in 2024 recommend iron supplementation for low ferritin levels, alpha-2-delta ligands like gabapentin for treatment, and non-pharmacological options like high-frequency bilateral peroneal nerve stimulation. The guidelines discourage the use of dopamine agonists and levodopa due to long-term complications, emphasizing safer alternatives.

Heart failure therapies are approved based on impact on patient well-being, function, or survival, with some approved solely on symptom, functional capacity, or quality of life improvements. Most trials use a composite of cardiovascular death or heart failure hospitalization (HHF) as the primary endpoint. Secondary analyses suggest non-cardiovascular hospitalizations contribute significantly to all-cause hospitalizations (ACH) in HF trials, especially in HFpEF patients. A meta-analysis found ACH reported in half of HF trials, with less than half of ACHs accounted for by HHF, indicating the importance of prespecification. The treatment effect on ACH is about half that on HHF, impacting sample size estimation. Empagliflozin trials illustrate diminished treatment effect on ACH when broadened beyond HF events. The choice between cause-specific and all-cause outcomes in HF trials should depend on the objective, with both outcomes important for comprehensive evaluation.

The EC fined Teva €462.6 million for abusing its dominant position to delay competition to Copaxone, marking the first time a pharma company was held liable for 'exclusionary disparagement.' This decision highlights the rising tide of antitrust enforcement against disparagement practices in the pharma sector, raising questions about the boundary between legitimate competition and illegal means.